• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma.

作者信息

Davis James, McGann Mary, Shockley Abigail, Hashmi Hamza

机构信息

Department of Malignant Hematology and Bone Marrow Transplant, Medical University of South Carolina, Charleston, South Carolina, USA.

出版信息

Expert Rev Hematol. 2022 Jun;15(6):473-475. doi: 10.1080/17474086.2022.2081147. Epub 2022 May 26.

DOI:10.1080/17474086.2022.2081147
PMID:35603733
Abstract
摘要

相似文献

1
Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma.伊德凯达基（idecabtagene vicleucel）与西达基奥仑赛（ciltacabtagene autoleucel）：复发难治性多发性骨髓瘤患者的艰难抉择。
Expert Rev Hematol. 2022 Jun;15(6):473-475. doi: 10.1080/17474086.2022.2081147. Epub 2022 May 26.
2
Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.西达基奥仑赛：用于治疗复发或难治性多发性骨髓瘤的第二款抗 BCMA CAR-T 细胞治疗武器。
Front Immunol. 2022 Sep 2;13:991092. doi: 10.3389/fimmu.2022.991092. eCollection 2022.
3
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.在治疗复发或难治性多发性骨髓瘤患者的 CARTITUDE-1 研究中比较 cilta-cabtagene autoleucel 与 idecabtagene vicleucel 的疗效结局的匹配调整间接比较。
Curr Med Res Opin. 2021 Oct;37(10):1779-1788. doi: 10.1080/03007995.2021.1953456. Epub 2021 Jul 23.
4
The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.美国用嵌合抗原受体 T 细胞疗法 cilta-cabtagene autoleucel 和 idecabtagene vicleucel 治疗成人复发性或难治性多发性骨髓瘤的经济负担。
BioDrugs. 2022 Nov;36(6):773-780. doi: 10.1007/s40259-022-00557-3. Epub 2022 Sep 27.
5
BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.BCMA 靶向嵌合抗原受体 T 细胞疗法治疗复发和/或难治性多发性骨髓瘤。
Ann Hematol. 2024 Apr;103(4):1069-1083. doi: 10.1007/s00277-023-05444-7. Epub 2023 Sep 13.
6
Sequence not salvage.序列无法挽救。
Br J Haematol. 2024 May;204(5):1590-1592. doi: 10.1111/bjh.19439. Epub 2024 Apr 2.
7
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.西达基奥仑赛，一种针对多发性骨髓瘤患者的 BCMA 靶向 CAR-T 疗法。
Expert Opin Biol Ther. 2024 May;24(5):339-350. doi: 10.1080/14712598.2024.2352591. Epub 2024 May 13.
8
Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.嵌合抗原受体 T 细胞疗法治疗骨髓瘤：我们现在处于什么位置，以及需要什么才能将嵌合抗原受体 T 细胞推进到更早的治疗线？美国移植和细胞治疗学会专家小组意见。
Transplant Cell Ther. 2024 Jan;30(1):17-37. doi: 10.1016/j.jtct.2023.10.022. Epub 2023 Oct 31.
9
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma.在骨髓瘤患者接受嵌合抗原受体 T 细胞（CAR T）治疗后的毒性和非复发死亡率的时间。
Transplant Cell Ther. 2024 Sep;30(9):876-884. doi: 10.1016/j.jtct.2024.06.012. Epub 2024 Jun 11.
10
BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.BCMA 靶向嵌合抗原受体 T 细胞疗法治疗多发性骨髓瘤。
Cancer Lett. 2023 Jan 28;553:215949. doi: 10.1016/j.canlet.2022.215949. Epub 2022 Oct 8.

引用本文的文献

1
Current landscape of innovative drug development and regulatory support in China.中国创新药物研发与监管支持的现状
Signal Transduct Target Ther. 2025 Jul 22;10(1):220. doi: 10.1038/s41392-025-02267-y.
2
Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products.CAR-T细胞疗法免疫原性的临床证据及其在CAR-T药物产品临床开发中的意义。
Front Immunol. 2025 Feb 21;16:1512494. doi: 10.3389/fimmu.2025.1512494. eCollection 2025.
3
Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database.
抗 B 细胞成熟抗原嵌合抗原受体 T 细胞治疗的安全性评估：基于 FDA 不良事件报告系统数据库的真实世界研究。
Front Immunol. 2024 Sep 3;15:1433075. doi: 10.3389/fimmu.2024.1433075. eCollection 2024.
4
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges.用于癌症治疗的下一代治疗性抗体：进展、应用与挑战
Mol Biotechnol. 2024 Sep 2. doi: 10.1007/s12033-024-01270-y.
5
Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective.CAR T 细胞疗法治疗多发性骨髓瘤的回顾：加拿大视角。
Curr Oncol. 2024 Jul 6;31(7):3949-3967. doi: 10.3390/curroncol31070292.
6
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies.血液恶性肿瘤中嵌合抗原受体 T 细胞耐药的机制。
Nat Rev Drug Discov. 2023 Dec;22(12):976-995. doi: 10.1038/s41573-023-00807-1. Epub 2023 Oct 31.
7
BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.BCMA 靶向嵌合抗原受体 T 细胞疗法治疗复发和/或难治性多发性骨髓瘤。
Ann Hematol. 2024 Apr;103(4):1069-1083. doi: 10.1007/s00277-023-05444-7. Epub 2023 Sep 13.
8
SOHO State-of-the-Art Updates and Next Questions | BCMA-Directed CAR T-Cells: Early Results and Future Directions.SOHO 最新进展及后续问题 | BCMA 靶向 CAR T 细胞：早期结果与未来方向。
Clin Lymphoma Myeloma Leuk. 2023 May;23(5):310-321. doi: 10.1016/j.clml.2023.01.017. Epub 2023 Feb 3.
9
Current and Future Perspectives for Chimeric Antigen Receptor T Cells Development in Poland.波兰嵌合抗原受体T细胞发展的现状与未来展望
Biomedicines. 2022 Nov 13;10(11):2912. doi: 10.3390/biomedicines10112912.
10
The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.美国用嵌合抗原受体 T 细胞疗法 cilta-cabtagene autoleucel 和 idecabtagene vicleucel 治疗成人复发性或难治性多发性骨髓瘤的经济负担。
BioDrugs. 2022 Nov;36(6):773-780. doi: 10.1007/s40259-022-00557-3. Epub 2022 Sep 27.